Next Stage for Biotron's Hep C Drug
Share
Follow Us
The Editors at Hepatitis Central
March 23, 2011
Australian biotech company, Biotron, concluded the first part of its Phase 2 trial evaluating BIT225, its Hepatitis C drug contender.
Biotron concludes Hepatitis C drug Phase 2 trial first stage
PBR Staff Writer
Published 11 March 2011
Biotron, an Australian biotechnology company developing and commercializing novel therapeutics and diagnostics to address a range of significant health issues, has concluded first part of its blinded Phase 2 trial evaluating BIT225, a drug to treat Hepatitis C virus infected patients.
Continue reading this entire article:
http://clinicaltrials.pharmaceutical-business-review.com/news/biotron-concludes-hepatitis-c-drug-phase-2-trial-first-stage-110311
